Editorial Policy

Our Research Process

Content starts with raw data from published research. We pull from peer-reviewed journals, regulatory filings, and clinical trial databases. No single source gets trusted on its own.

Each peptide goes through our content pipeline: data collection, cross-referencing against multiple sources, validation of dosing numbers, and a final review pass. The "Last reviewed" date on each page shows when that cycle last completed.

Source Hierarchy

Not all evidence is equal. Here's how we rank sources when they conflict:

1. 1
   FDA labels and approved prescribing information. When available, this is the gold standard.
2. 2
   Published clinical trials in humans. Randomized controlled trials carry the most weight. Open-label and observational studies less so.
3. 3
   Peer-reviewed review articles and meta-analyses. Good for big-picture context and consensus views.
4. 4
   Preclinical studies (animal and in-vitro). We always label these as such. Animal data doesn't automatically apply to humans.
5. 5
   Aggregated community protocols. When no clinical dosing data exists, we reference established protocols from experienced practitioners and community reports. These are clearly labeled as community-sourced. They reflect what people actually use — not what's been proven in a controlled trial.

Fact-Checking

Every dosing number gets cross-referenced against at least 2 independent sources. If two sources disagree by more than 2x on a dose, it gets flagged for manual review. We don't publish numbers we can't verify.

Our content pipeline tracks each page through these stages: data collection → cross-referencing → validated → published. Only validated content goes live.

Update Cadence

We review each peptide page on a regular cycle. The "Last reviewed" date at the top of each page shows when we last checked the data against current sources. If new research changes dosing recommendations or safety profiles, we update immediately rather than waiting for the next review cycle.

What Our Badges Mean

Safety Grades

• Grade A — Strong safety profile. Backed by extensive human data or long-established use with minimal reported issues.
• Grade B — Good safety profile. Some human data exists, or extensive community use with few reported concerns.
• Grade C — Use caution. Limited human data. Safety profile based primarily on preclinical research and community reports.
• Grade D — Higher risk. Very limited data. Reported side effects or safety concerns from research or community use.

Research Levels

• FDA Approved — Approved by the FDA for at least one indication.
• Extensively Studied — Multiple large clinical trials in humans.
• Well-Researched — Human trial data exists, though it may be limited.
• Emerging Research — Mostly preclinical data. Human trials are early or ongoing.
• Limited Research — Very little published data. Treat claims cautiously.

Regulatory Status

Shows where a peptide stands in the regulatory process: FDA-approved, Phase 1-3 clinical trials, preclinical, or research-only. This isn't a recommendation — it's a factual description of regulatory status.